Overview
CSTONE PHARMA-B (2616)
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Main...
- Open
- 5.110
- High
- 5.230
- Low
- 5.010
- Prev. Close
- 5.205
- Volume
- 5.26M
- Turnover
- 27.10M
- Avg Price
- 5.151
- Bid/Ask Ratio
- -61.70%
- Amplitude
- 4.23%
- 52wk High
- 10.410
- Volume Ratio
- 0.66
- Turnover Ratio
- 0.33%
- 52wk Low
- 4.010
- HK Mkt Cap
- 8.23B
- Market CapHKD
- 8.23B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.302
- EPSDynamic
- -0.364
- EPSStatic
- --
- BVPS
- 0.93
- P/B
- 5.53
- HK Shares
- 1.60B
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 1.60B
- Min lot size
- 500
- Currency
- HKD
CSTONE PHARMA-B Analyst Rating
View moreForecast & Rating
Oct 29, 2026- Strong buy66.67%
- Buy33.33%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 2
- Buy
- 1
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
The stock dipped 0.96% to HK$5.155 today, primarily attributable to profit-taking following the recent Kimia Therapeutics clinical collaboration announcement. Q2 earnings released show operating revenue of HK$1.1845 billion, up 337.19% year-over-year, reflecting accelerating sales of flagship products including avelumab, pralsetinib, and sugemalimab; despite net loss of HK$145.7 million, the loss margin narrowed compared to the year-earlier period. The lead candidate CS2009 demonstrated 87.5% response rate in first-line PD-L1-high lung cancer with data from over 300 patients, supporting its mechanism and safety profile. The stock trades 50.48% below its 52-week high of HK$10.41 but has rebounded 28.55% from the June low of HK$4.01; year-to-date it has declined 3.46%; current price sits above the 20-day moving average but notably below the 60-day average. However, the company remains unprofitable with earnings power still requiring validation.
- Nov, 13
Today's decline of approximately 4.8% to HKD 5.205 reflects profit-taking pressure following a series of positive catalysts, despite the company's revenue momentum. Key catalysts include: CS2009 data presented at ESMO 2026 conference demonstrating an impressive 87.5% response rate in first-line PD-L1-high lung cancer patients among 300+ study participants, coupled with a newly announced partnership with Kimia Therapeutics for solid-tumor drug development. While these milestones had previously driven share appreciation, investors are now realizing profits. On the earnings front, Q2 revenue climbed to HKD 118.4 million, representing substantial 337% year-over-year growth; however, the company remains in a loss-making phase with a net profit margin of -123%, typical for biotech firms in clinical-to-commercial transition. Regarding valuation, the stock has retreated 50% from its 52-week high of HKD 10.41, currently trading above its 20-day moving average of 5.09 but below the 60-day average of 5.46.
- Nov, 12
CStone Pharma declined 0.27% to close at HKD 5.465, consolidating recent gains after multiple positive catalysts. The company recently announced a strategic collaboration with Kimia Therapeutics on solid-tumor drug development and disclosed clinical data from ESMO 2026 showing CS2009 achieved an impressive 87.5% response rate in first-line PD-L1-high lung cancer. These milestones drove a weekly gain of 7.98%. On the financial side, Q2 operating revenue surged to HKD 118.4 million, up 337% year-over-year, reflecting strong commercial momentum for its key products. However, the company remains unprofitable with a net loss of HKD 145.7 million and a net margin of −123%, indicating heavy R&D and commercialization costs. Regarding valuation, the stock is up 2.34% year-to-date but has retreated 47.5% from its 52-week high of HKD 10.41 reached in April, currently trading near the 60-day moving average of HKD 5.457. While the clinical progress and partnerships are encouraging, the ongoing losses and negative earnings multiple highlight execution risks that investors should monitor.
- Nov, 11
CStone Pharmaceuticals closed flat at HK$5.48, after an intraday surge to HK$5.54 in morning trading before retreating. The early momentum was driven by positive sentiment from the recently-announced Kimia Therapeutics collaboration on solid-tumor drug development. Q2 2026 revenues reached HK$118.4 million, soaring 337% year-over-year, supported by sales of Apatinib (泰吉华) and Pralsetinib (普吉华), while pipeline asset CS2009 demonstrated an encouraging 87.5% response rate in first-line PD-L1-high lung cancer patients. The company posted a net loss of HK$145.7 million in the quarter, though the loss margin narrowed 1.57% year-on-year. From a valuation perspective, the stock remains 47.36% below its 52-week high of HK$10.41, with year-to-date gains of only 2.62%, indicating significant repricing from prior peaks despite recent positive catalysts.
- Nov, 10
CStone Pharma advanced 1.29% to HKD 5.48 today, supported by recent clinical partnership announcements and robust trial data momentum. The company recently unveiled a solid-tumor drug development collaboration with Kimia Therapeutics, capitalizing on strong showings from its lead asset CS2009, which demonstrated an impressive 87.5% response rate in first-line PD-L1-high lung cancer patients. Year-to-date, the stock has accumulated a 2.62% gain from its lows, though it trades 47.36% below the 52-week high of HKD 10.41, suggesting persistent valuation pressure despite recent wins. On the earnings front, Q2 revenue surged 337.19% year-over-year to HKD 118.4 million, underscoring rapid commercialization execution, yet the company posted a substantial net loss of HKD 145.7 million with a net margin of -123%, indicating a protracted runway to profitability. With a market cap of approximately HKD 8.75 billion and a modest 0.32% turnover rate, CStone remains in an inflection phase where clinical validation must translate into financial sustainability.
News
Weekly Review · Weekly Recap | CSTONE PHARMA-B -3.79%, most brokers rate it buy
Weekly Review · Weekly Recap | CSTONE PHARMA-B +7.98%, Kimia clinical collaboration announced
Market Movers · CSTONE PHARMA-B fell approximately 6%
Market Movers · Cstone Pharma climbs 6% on Kimia Therapeutics collaboration
Tip Ranks · CStone and Kimia Partner on Solid-Tumor Drug Development
